Charles River Laboratories International, Inc. (CRL)
Charles River Laboratories International, Inc. (CRL) is a healthcare company (diagnostics & research) based in the United States. The share price is $334.83, down 0.21% on the day, which values the company at $16.04B. Price as of 17 Nov 2026, 17:15 UTC, from Yahoo Finance.
Key facts
- Share price
- $334.83−0.21% today
- Market value
- $16.04B
- P/E ratio
- 363.9×last 12 months
- Forward P/E
- 25.8×
- Funk Score
- 38/100
- Against its own history
- Well above its usual priceusual price $195.55
- 200-week average
- $201.9366% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Charles River Laboratories International, Inc. in more detail
CRL trades at 363.9× its last twelve months' earnings, 25.8× next year's expected earnings, 4.0× sales. Measured against its own history, the price is 71% above what its usual multiples would imply ($195.55) — well above its usual price. It sits 66% above its 200-week average of $201.93.
Over the last five fiscal years Charles River Laboratories International, Inc. has compounded revenue 6.5% a year, free cash flow 6.4% a year. Its Funk Score is 38 out of 100 (financial strength 3.8, profitability 4.0, growth 3.8, value 3.5, each out of 10).
In its favour: Altman Z in the safe zone.
7 of the superinvestors tracked here hold CRL, including John Rogers (3.7% of the portfolio), Anthony Bozza (0.9% of the portfolio), Bill Nygren (0.7% of the portfolio).
Superinvestors holding CRL
7 of the investors tracked here report a position in their latest 13F filing.
- John Rogers Ariel Investments3.66% of portfolio · $352M · trimmed · Q3 2026
- Anthony Bozza Lakewood Capital0.90% of portfolio · $16.7M · trimmed · Q3 2026
- Bill Nygren Harris Associates (Oakmark)0.68% of portfolio · $508.3M · added · Q2 2026
- Karthik Sarma SRS Investment Management0.54% of portfolio · $57.3M · added · Q3 2026
- Joel Greenblatt Gotham Asset Management0.23% of portfolio · $98.2M · added · Q2 2026
- Ken Griffin Citadel Advisors0.16% of portfolio · $270.7M · trimmed · Q2 2026
- Murray Stahl Horizon Kinetics0.02% of portfolio · $1.9M · trimmed · Q3 2026
Health Care companies of similar size
- Guardant HealthGH
- Alnylam PharmaceuticalsALNY
- Zimmer Biomet HoldingsZBH
- Medpace HoldingsMEDP
- RevvityRVTY
- ExelixisEXEL
- Neurocrine BiosciencesNBIX
- Ascendis PharmaASND
- ICONICLR
- Jazz PharmaceuticalsJAZZ
- SolventumSOLV
- BridgeBio PharmaBBIO
Side by side:CRL vs NBIX (Charles River Laboratories International, Inc. vs Neurocrine Biosciences)CRL vs EXEL (Charles River Laboratories International, Inc. vs Exelixis)CRL vs ASND (Charles River Laboratories International, Inc. vs Ascendis Pharma)CRL vs RVTY (Charles River Laboratories International, Inc. vs Revvity)CRL vs MEDP (Charles River Laboratories International, Inc. vs Medpace Holdings)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Charles River Laboratories International, Inc. (CRL): questions and answers
What is CRL's P/E ratio?
Charles River Laboratories International, Inc. trades at 363.9× its last twelve months' earnings and 25.8× next year's expected earnings. At its fiscal year-ends over the past 14 years the P/E ranged from 12.8× to 49.6×, with a median of 24.8×.
What is CRL's PEG ratio?
Charles River Laboratories International, Inc.'s PEG ratio is 0.12 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Charles River Laboratories International, Inc.'s market cap?
Charles River Laboratories International, Inc. is valued at $16.04B at a share price of $334.83.
Is CRL overvalued or undervalued?
Against its own history, CRL is well above its usual price: the price is 71% above the $195.55 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is CRL above its 200-week moving average?
Yes. CRL is 65.8% above its 200-week average of $201.93. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Charles River Laboratories International, Inc. growing?
Over the last five fiscal years Charles River Laboratories International, Inc.'s revenue grew 6.5% a year; over ten years revenue grew 11.4% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Charles River Laboratories International, Inc. (CRL) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/CRL
Underlying data: Yahoo Finance; company filings with the SEC.